Salarius Pharmaceuticals Financials
| SLRX Stock | USD 0.96 0.01 1.05% |
Salarius |
Please note, the imprecision that can be found in Salarius Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Salarius Pharmaceuticals. Check Salarius Pharmaceuticals' Beneish M Score to see the likelihood of Salarius Pharmaceuticals' management manipulating its earnings.
Salarius Pharmaceuticals Stock Summary
Salarius Pharmaceuticals competes with Akari Therapeutics, Nutriband, SAB Biotherapeutics, GeoVax Labs, and Corvus Pharmaceuticals. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US79400X4043 |
| CUSIP | 33938A105 79400X107 79400X305 79400X404 |
| Location | Texas; U.S.A |
| Business Address | 2450 Holcombe Boulevard, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.salariuspharma.com |
| Phone | 832 834 9144 |
| Currency | USD - US Dollar |
Salarius Pharmaceuticals Key Financial Ratios
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.53 | ||||
| Target Price | 26.0 | ||||
| Beta | 0.59 |
Salarius Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Salarius Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Salarius Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Salarius Pharmaceuticals competition to find correlations between indicators driving Salarius Pharmaceuticals's intrinsic value. More Info.Salarius Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Salarius Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Salarius Pharmaceuticals Systematic Risk
Salarius Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Salarius Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Salarius Pharmaceuticals correlated with the market. If Beta is less than 0 Salarius Pharmaceuticals generally moves in the opposite direction as compared to the market. If Salarius Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Salarius Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Salarius Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Salarius Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Salarius Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Salarius has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Salarius Pharmaceuticals' financials are consistent with your investment objective using the following steps:- Review Salarius Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Salarius Pharmaceuticals' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Salarius Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Salarius Pharmaceuticals' stock is overvalued or undervalued.
Salarius Pharmaceuticals March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Salarius Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Salarius Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Salarius Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Salarius Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Salarius Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.71 | |||
| Information Ratio | 0.0226 | |||
| Maximum Drawdown | 161.82 | |||
| Value At Risk | (11.25) | |||
| Potential Upside | 11.41 |
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.